Background: COVID-19 has had a significant impact on the well-being and job performance of oncology professionals globally. The European Society for Medical Oncology (ESMO) Resilience Task Force collaboration set out to investigate and monitor well-being since COVID-19 in relation to work, lifestyle and support factors in oncology professionals 1 year on since the start of the pandemic.

Methods: An online, anonymous survey was conducted in February/March 2021 (Survey III). Key outcome variables included risk of poor well-being or distress (expanded Well-Being Index), feeling burnout (single item from expanded Well-Being Index), and job performance since COVID-19. Longitudinal analysis of responses to the series of three surveys since COVID-19 was carried out, and responses to job demands and resources questions were interrogated. SPSS V.26.0/V.27.0 and GraphPad Prism V9.0 were used for statistical analyses.

Results: Responses from 1269 participants from 104 countries were analysed in Survey III: 55% (n = 699/1269) female, 54% (n = 686/1269) >40 years, and 69% (n = 852/1230) of white ethnicity. There continues to be an increased risk of poor well-being or distress (n = 464/1169, 40%) and feeling burnout (n = 660/1169, 57%) compared with Survey I (25% and 38% respectively, P < 0.0001), despite improved job performance. Compared with the initial period of the pandemic, more participants report feeling overwhelmed with workload (45% versus 29%, P < 0.0001). There remain concerns about the negative impact of the pandemic on career development/training (43%), job security (37%). and international fellowship opportunities (76%). Alarmingly, 25% (n = 266/1086) are considering changing their future career with 38% (n = 100/266) contemplating leaving the profession.

Conclusion: Oncology professionals continue to face increased job demands. There is now significant concern regarding potential attrition in the oncology workforce. National and international stakeholders must act immediately and work closely with oncology professionals to draw up future-proof recovery plans.

Key words: well-being, burnout, job performance, oncology professionals, resilience, COVID-19
INTRODUCTION
The discovery of the novel coronavirus SARS-CoV-2 in Wuhan, China in late December 2019 and the official declaration of the COVID-19 pandemic in March 2020, has triggered unprecedented changes to health systems worldwide, with cancer services being no exception.\(^1\)\(^,\)\(^2\) Globally, oncology services have experienced significant disruption due to staff redeployment, deterioration in working conditions, reduction in oncology clinical trials, and research activities.\(^3\)\(^-\)\(^5\) Additional temporising measures such as suspension of ‘non-essential’ palliative chemotherapy, cancer screening services, and favouring of less intensive treatment regimens have also impacted the nature of our work with potential for longer-term consequences.\(^6\)\(^-\)\(^9\)

Since the COVID-19 pandemic, clinicians have been particularly challenged in their ability to provide cancer care to aspired standards with a concomitant diminution in meaningful professional activities.\(^4\)\(^,\)\(^5\) All of this whilst also contending with the risk to personal safety at work from COVID-19 infection and associated morbidity.\(^5\) The European Society for Medical Oncology (ESMO) Resilience Task Force launched a unique longitudinal series of global surveys since April 2020 to provide contemporary insights into the daily practice and well-being of oncology professionals during the COVID-19 pandemic. Our findings from Survey I conducted in April/May 2020 and Survey II in July/August 2020 indicated that COVID-19 has had a detrimental impact on the lives of oncology professionals with rising rates of distress and burnout, and uncovered significant concerns regarding job security and their future outlook.\(^4\)\(^,\)\(^5\) Here, we provide a further update 1 year on reporting on the key findings from Survey III conducted in February/March 2021.

METHODS
Survey design
Survey III followed on from the series of online global surveys designed by the ESMO Resilience Task Force, in collaboration with the ESMO Young Oncologists Committee, ESMO Women for Oncology Committee, ESMO Leaders Generation Programme Alumni members, and the OncoAlert Network, launched at specific timepoints during the course of the COVID-19 pandemic. Survey III was hosted on the Qualtrics platform (open from 9 February 2021 to 3 March 2021) and was available on the ESMO website, ESMO membership emails, and was promoted through social media. Participation was voluntary and anonymous. Participants who consented to longitudinal evaluation of their responses at different timepoints of the survey series were assigned a trackable unique identifier code. The project was approved by the ESMO Executive Board.

Survey measures
Key outcome variables used throughout the survey series including risk of poor well-being or distress (expanded Well-Being Index, eWBI; score ≥4, at risk),\(^10\)\(^,\)\(^11\) feeling burnout (single item from eWBI), and job performance since COVID-19 (JP-CV; score ≥3.5, favourable) have been previously described in detail.\(^4\)\(^,\)\(^5\) In Survey III, we also added relevant questions regarding participants’ perception of the COVID-19 situation in their respective country of work including lockdown restrictions and national vaccination programmes. Further questions about participants’ personal experience of COVID-19, and their personal and professional future outlook were also included. In total, there were 38 closed response questions with 1 open text response question at the end of the survey.

Statistical analysis
Key outcome variables: eWBI, burnout, and JP-CV were longitudinally compared with results from Surveys I\(^4\) and II.\(^5\) Chi-square analysis was used to compare categorical variables and paired or unpaired t-tests were used to analyse continuous variables. We also carried out the chi-square test for trend when comparing proportions across time (Survey I versus Survey II versus Survey III, where data available). P values were two-tailed and were considered significant if <0.05. A series of cross-sectional between-subject analyses were also carried out in a subgroup of participants who completed all three surveys to examine relationships over time. Descriptive data were presented as median (interquartile range) or mean ± standard deviation, and proportions were expressed as a percentage (%). All statistical analyses were carried out using SPSS V.26.0 or V.27.0 (IBM Corp., Armonk, NY) and data represented using GraphPad Prism V9.0 (GraphPad Software, San Diego, CA).

RESULTS
Participant demographics
A total of 1432 participants from 104 countries responded to the Survey III invitation. In the final analysis, we included data from all participants who consented and responded to key questions placed at the beginning of the survey on their perception of the current status of COVID-19 (trend, lockdown, and vaccination) and provided basic demographic details including their country of work \(n = 1269\) (88.6%). The majority \(n = 1158/1269, 91.3\%\) completed the survey to the end. The personal and professional demographic characteristics of Survey III participants are outlined in Table 1 and Supplementary Table S1, available at https://doi.org/10.1016/j.esmoop.2021.100374. Overall, 55.1\% \(n = 699/1269\) were female, 54.1\% \(n = 686/1269\) >40 years of age, and 69.3\% \(n = 852/1230\) of white ethnicity. Collectively, participants have a mean of 15 years of experience working in oncology, with medical oncology most represented \(n = 905/1245, 72.7\%\). Trainees contributed to 22.1\% \(n = 281/1269\) of responses. The majority of respondents were ESMO members \(n = 1073/1238, 86.7\%\) and were from Europe \(n = 854/1269, 67.3\%\) (Supplementary Table S1, available at https://doi.org/10.1016/j.esmoop.2021.100374).

---

2 https://doi.org/10.1016/j.esmoop.2021.100374
Table 1. Participant demographics for Survey III (n = 1269)

|                          | Number, n (%) |
|--------------------------|---------------|
| Age (years), n = 1269    |               |
| ≤40                      | 583 (45.9)    |
| >40                      | 686 (54.1)    |
| Gender, n = 1269         |               |
| Female                   | 699 (55.1)    |
| Male                     | 566 (44.6)    |
| Prefer not to say        | 4 (0.3)       |
| Ethnicity, n = 1230      |               |
| White                    | 852 (69.3)    |
| Asian (East/Southeast)   | 156 (12.7)    |
| Asian (South)            | 63 (5.1)      |
| Hispanic                 | 59 (4.8)      |
| Arab                     | 32 (2.6)      |
| Mixed                    | 17 (1.4)      |
| Black                    | 16 (1.3)      |
| Other                    | 17 (1.4)      |
| Prefer not to say        | 18 (1.5)      |
| Lives alone, n = 1232    |               |
| Yes                      | 187 (15.2)    |
| No                       | 1045 (84.8)   |
| Have children/dependents, n = 1232 |          |
| Yes                      | 738 (59.9)    |
| No                       | 494 (40.1)    |
| Region, n = 1269         |               |
| Europe†                 |               |
| Southwestern Europe      | 264 (20.8)    |
| Central Europe           | 220 (17.3)    |
| Northern Europe and British Isles | 175 (13.8) |
| Southeastern Europe      | 87 (6.9)      |
| Western Europe           | 78 (6.1)      |
| Eastern Europe           | 30 (2.4)      |
| Asia                    | 223 (17.6)    |
| North America            | 78 (6.1)      |
| South America            | 56 (4.4)      |
| Africa                   | 43 (3.4)      |
| Oceania                  | 15 (1.2)      |
| Primary place of work, n = 1238 |          |
| General hospital         | 628 (50.7)    |
| Cancer centre            | 460 (37.2)    |
| Private outpatient clinic | 21 (1.7)      |
| Pharmaceutical/technology company | 44 (3.6) |
| Health care organisation | 21 (1.7)      |
| Other                    | 64 (5.2)      |
| Speciality, n = 1245     |               |
| Medical oncology         | 905 (72.7)    |
| Radiation/clinical oncology | 177 (14.2) |
| Haematology              | 130 (10.4)    |
| Palliative care          | 75 (6.0)      |
| Surgical oncology        | 44 (3.5)      |
| Laboratory-based researcher/scientist | 38 (3.1) |
| Nursing                  | 11 (0.9)      |
| Other                    | 81 (6.5)      |
| Trainee, n = 1269        |               |
| Yes                      | 281 (22.1)    |
| No                       | 988 (77.9)    |
| ESMO member, n = 1238    |               |
| Yes                      | 1073 (86.7)   |
| No                       | 165 (13.3)    |

See also Supplementary Table S1, available at https://doi.org/10.1016/j.esmoop.2021.100374 for further details of countries/regions represented.

ESMO, European Society for Medical Oncology.

†Countries most represented in Survey III were UK (n = 112), Germany (n = 99), Spain (n = 98), Italy (n = 85), Portugal (n = 81), and India (n = 78). See Supplementary Table S1, available at https://doi.org/10.1016/j.esmoop.2021.100374 for complete list of countries/regions, and the corresponding number of participants per country.

‡Southwestern Europe—Italy, Portugal, Spain; Central Europe—Austria, Czech Republic, Germany, Hungary, Poland, Romania, Slovakia, Slovenia, Switzerland; Northern Europe and the British Isles—Denmark, Finland, Norway, Republic of Ireland, Sweden; UK; Southeastern Europe—Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Greece, Israel, Kosovo, Montenegro, North Macedonia, Serbia, Turkey; Western Europe—Belgium, France, Luxembourg, The Netherlands; and Eastern Europe—Belarus, Estonia, Georgia, Latvia, Lithuania, Moldova, Russian Federation, Ukraine.

Note that some participants have selected two or more specialties within their job role (to encompass differences in the scope of practice between countries/regions), and proportion of representation is summarised as such. Overall, participants have reported a mean of 15.1 ± 10.5 years of experience in the field of oncology.

Table 2. Personal experience of COVID-19 as reported by participants in Survey III (n = 1269), reflecting the period from February to March 2021

| Perception of COVID-19 death rate in region of work | Number, n (%) |
|----------------------------------------------------|---------------|
| Increasing                                         | 536 (42.2)    |
| No change                                          | 176 (13.9)    |
| Decreasing                                         | 533 (42.0)    |
| Free of COVID-19                                    | 24 (1.9)      |

| Current restrictions in region of work              | Number, n (%) |
|----------------------------------------------------|---------------|
| Full lockdown                                       | 280 (22.1)    |
| Partial lockdown                                    | 718 (56.6)    |
| End of lockdown                                     | 157 (12.4)    |
| No lockdown imposed so far                          | 114 (9.0)     |

| Current status of COVID-19 vaccination programme in country of work | Number, n (%) |
|---------------------------------------------------------------------|---------------|
| National programme has started                                      | 1112 (87.6)   |
| National programme planned but has not started yet                  | 138 (10.9)    |
| No plans for a national programme so far                            | 19 (1.5)      |

| Personally received vaccination against COVID-19                  | Number, n (%) |
|---------------------------------------------------------------------|---------------|
| Yes, 2 doses                                                       | 554 (43.7)    |
| Yes, 1 dose                                                       | 295 (23.2)    |
| No                                                                  | 408 (32.2)    |
| Prefer not to say                                                  | 12 (0.9)      |

| Regular asymptomatic testing for COVID-19, n = 1082                | Number, n (%) |
|---------------------------------------------------------------------|---------------|
| Yes                                                                  | 423 (39.1)    |
| No                                                                  | 659 (60.9)    |

| Have had to undergo isolation/take sick leave due to COVID-19 symptoms, n = 1080 | Number, n (%) |
|-----------------------------------------------------------------------------------|---------------|
| Yes                                                                              | 263 (24.4)    |
| No                                                                              | 817 (75.6)    |

| Tested positive for COVID-19, n = 1081                                          | Number, n (%) |
|---------------------------------------------------------------------------------|---------------|
| Yes                                                                            | 160 (14.8)    |
| No                                                                             | 921 (85.2)    |

| Required hospitalisation for COVID-19, n = 160                                  | Number, n (%) |
|---------------------------------------------------------------------------------|---------------|
| Yes                                                                            | 10 (6.3)      |
| No                                                                             | 150 (93.8)    |

| Feel given appropriate time to recover (if had symptomatic COVID-19), n = 160 | Number, n (%) |
|-----------------------------------------------------------------------------|---------------|
| Yes                                                                          | 117 (73.1)    |
| No                                                                           | 43 (26.9)     |

| Feel completely recovered upon return to work, n = 160                      | Number, n (%) |
|-----------------------------------------------------------------------------|---------------|
| Yes                                                                          | 100 (62.5)    |
| No                                                                           | 60 (37.5)     |

| Had colleague who has died from COVID-19, n = 1079                            | Number, n (%) |
|-----------------------------------------------------------------------------|---------------|
| Yes                                                                          | 215 (19.9)    |
| No                                                                           | 841 (77.9)    |
| Prefer not to say                                                           | 23 (2.1)      |

**Personal experience with COVID-19**

As the COVID-19 pandemic continues, the majority of participants have encountered some form of lockdown restrictions in their region of work (Table 2). Almost all participants (n = 1250/1269, 98.5%) reported that a national vaccination programme against COVID-19 was underway, if not planned, and two-thirds (n = 849/1269, 66.9%) have personally had at least one dose of the vaccine when asked in February/March 2021 (Table 2).
More than a third of participants reported having regular asymptomatic testing for COVID-19 (n = 423/1082, 39.1%) (Table 2). A total of 160 participants (14.8%) had tested positive for COVID-19, of whom 10 had required hospitalisation. Of those who had tested positive for COVID-19, a third (n = 43/160, 26.9%) neither felt they had been given appropriate time to recover nor felt completely recovered upon their return to work (n = 60/160, 37.5%). By February/March 2021, one in five participants disclosed that they had a work colleague who died of COVID-19 (n = 215/1079, 19.9%).

**Ongoing changes in professional role and delivery of care**

Work routine has yet to return to the pre-COVID-19 situation for more than half of participants (n = 578/1269, 52.3%). In Survey III, around a fifth of participants (n = 238/1107, 21.5%) were either partially or fully redeployed. Participants continued to report several changes to their professional roles and duties as detailed in Supplementary Table S2, available at https://doi.org/10.1016/j.esmoop.2021.100374, with nearly half (n = 354/756, 46.8%) reporting an increase in overall hours of work. As expected, there remained an increased use of remote or virtual meetings and consultations (>80%). Of concern, more than half of participants reported a decrease in clinical trial activity (n = 392/648, 60.5%) and general research activity (n = 366/664, 55.1%). About two-thirds of participants (n = 708/1108, 63.9%) were worried that COVID-19 would have a negative impact on the quality of cancer research at their institution.

**Well-being, burnout, and resilience throughout the pandemic**

Compared with Surveys I^4 and II^5, there were now significantly more participants who were at risk of poor well-being or distress (n = 464/1169, 39.7%) and feeling burnout (n = 660/1169, 56.5%) (chi-square test for trend, P < 0.0001) (Figure 1A and B). These trends were confirmed in a longitudinal subgroup of n = 127 participants from 47 countries (50.0% female, 39.4% ≤40 years old, and 69.3% of white ethnicity) who had completed all three surveys, in whom there was a progressive increase in the proportion of those at risk of poor well-being (20.5% versus 28.9% versus 31.6%, P = 0.0516) and feeling burnout (34.4% versus 47.9% versus 56.4%, P = 0.0006) (Supplementary Figure S1A and B, 2023).
These observations are despite the perception of improved job performance, where JP-CV plateaued at \( \geq 50\% \) since the Survey II timepoint (Figure 1C and Supplementary Figure S1C, available at [https://doi.org/10.1016/j.esmoop.2021.100374](https://doi.org/10.1016/j.esmoop.2021.100374)). Of note, there appear to be sustained levels of psychological resilience amongst participants throughout the pandemic (Supplementary Figure S2, available at [https://doi.org/10.1016/j.esmoop.2021.100374](https://doi.org/10.1016/j.esmoop.2021.100374)). As gender and age were found to be significant predictors of risk of poor well-being in Survey I,\(^4\) we assessed whether this disparity persisted over the course of the COVID-19 pandemic. Female colleagues continued to be at higher risk of poor well-being \( (OR 1.643 \ [95\% CI 1.298-2.091], \ P < 0.0001) \) and feeling burnout \( (OR 1.859 \ [95\% CI 1.469-2.342], \ P < 0.0001) \) (Figure 2). Similarly, younger \(( \leq 40\text{ years} \ (n = 533))\) colleagues were also at continued risk of poor well-being \( (OR 1.987 \ [95\% CI 1.562-2.519], \ P < 0.0001) \) and feeling burnout \( (OR 1.444 \ [95\% CI 1.144-1.825], \ P = 0.002) \) (Figure 2).

**Factors contributing to perception of increased job demands**

We analysed responses to questions associated with job demands over the different timepoints studied in this survey series to identify reasons which may have potentially contributed to worsening distress and burnout (Figure 3A). A chi-square test for trend was carried out to compare responses to Survey I versus Survey II versus Survey III.

![Figure 2. Subgroup comparisons of key outcome variables (risk of poor well-being/distress and burnout) analysed by (A) age and (B) gender, respectively, of participants in Survey III. Groups were compared using chi-square analyses.](https://doi.org/10.1016/j.esmoop.2021.100374)

Alarmingy, we observed that in general there has been a progressive increase in job demands, with considerable increases in the proportion of participants who have reported an increase in the perception of feeling overwhelmed with workload \( (29.1\% \text{ versus } 35.6\% \text{ versus } 45.2\%, \ P < 0.0001) \) and overall working hours \( (16.7\% \text{ versus } 38.4\% \text{ versus } 46.8\%, \ P < 0.0001) \) (Figure 3A). Moreover, more participants were now also burdened with increased COVID-19 inpatient work \( (13.6\% \text{ versus } 40.3\% \text{ versus } 58.1\%, \ P < 0.0001) \) and COVID-19-related research \( (15.6\% \text{ versus } 58.7\% \text{ versus } 64.5\%, \ P < 0.0001) \). Whereas the majority have continued to work in pleasant physical conditions, their concern for personal safety at work due to COVID-19 has remained persistently high \( (78.3\% \text{ versus } 72.5\% \text{ versus } 63.0\%, \ P < 0.0001) \) (Figure 3A).

Almost half \(( n = 527/1169, 45.1\% )\) were reporting having inadequate time for personal and/or family life compared with \( 34.6\% \ ( n = 526/1520) \) and \( 43.0\% \ ( n = 405/942) \) in Surveys I\(^4\) and II\(^5\), respectively (Figure 3A). Moreover, the majority of participants in Survey III reported that they had not been able to take time off for annual leave or holidays \( ( n = 650/1084, 60.0\% ) \), and/or study leave \( ( n = 863/1084, 79.6\% ) \) (Figure 3A).

**Personal and professional job resources currently available**

In addition, we also interrogated several domains in terms of personal and professional resources and coping strategies available to participants which could potentially...
Figure 3. Heatmaps of factors which may be contributing to worsening distress and feeling burnout since COVID-19.
alleviate job demands (Figure 3B). Here, the main areas of concern were regarding job security and participants’ support systems (Figure 3B). In particular, participants were concerned that the pandemic would have a negative impact on their personal job security (n = 386/1057, 36.5%). Just more than a third of participants (n = 346/1023, 33.8%) were not concerned that the COVID-19 pandemic would have a negative impact on their personal career development/training, and very few were not concerned about international fellowship opportunities (n = 116/973, 11.9%) (Figure 3B).

Participants were questioned about their support systems, access to well-being support services, and the coping strategies they had been using to help themselves during the pandemic (details summarised in Figure 3B, and Supplementary Table S3, available at https://doi.org/10.1016/j.esmoop.2021.100374). There has been a gradual decline in the proportion of participants who felt well supported by the management at their workplace since Survey I, with now less than half (n = 476/1058, 45.0%) feeling well supported (Figure 3B). Similarly, their perception of support from global and/or national societies/groups and governments had declined over time (56.8% versus 50.7% versus 41.7%, P < 0.0001) (Figure 3B). Overall, in Survey III, 59.5% (n = 635/1068) reported having adequate resources to do their jobs (Figure 3B). There has also been a decrease in the proportion of participants who felt valued by their work organisation (59.7% versus 53.7% versus 50.8%, P < 0.0001) and the public (75.1% versus 63.9% versus 57.0%, P < 0.0001) (Supplementary Table S3, available at https://doi.org/10.1016/j.esmoop.2021.100374).

Whereas access to well-being support services was only perceived as available for less than half of participants (n = 472/1077, 43.8%), this represented a reassuring increase compared with the pre-pandemic level (n = 210/1076, 19.5%) (P < 0.0001) (Supplementary Table S3, available at https://doi.org/10.1016/j.esmoop.2021.100374).

**Potential risk of workforce attrition**

Finally, in Survey III, concerns with regards to attrition in the oncology workforce were flagged. A quarter of participants (n = 266/1086, 24.5%) disclosed that they had considered changing their future career, with 37.6% (n = 100/266) thinking of leaving the oncology profession and 27.8% (n = 74/266) considering moving to work in industry.

**DISCUSSION**

Survey III draws on the lived experiences of 1269 oncology professionals from 104 countries to shed light on the ongoing deterioration in well-being in oncology and raise the significant threat of workforce attrition. A year on since the COVID-19 pandemic, there is marked increase in risk of poor wellbeing/distress (40% versus 25%) and burnout (57% versus 38%) compared with Survey I (April/May 2020).4 Job demands have continued to increase, meanwhile there appears to be a perceived decline in clinical trial activity and research, career development opportunities, and available resources and support. Almost half of survey participants now feel overwhelmed with their workload.

Female and younger (< 40 years) colleagues continue to be at higher risk of poor well-being and burnout, two demographic groups noted to be particularly vulnerable in our previous surveys4,5 and in the published literature.12,13 There is evidence that the pandemic has had an unequal impact on gender, with female clinicians shouldering the greater burden of domestic responsibilities which may be exacerbating the pressure of growing professional demands.14,15 In Survey II, we previously highlighted concerns raised regarding career development, training, and job security disproportionately impacting trainee and early-career oncologists.5 Survey III broadens these concerns to that of a more widespread impending crisis in workforce retention. Alarmingly, one in four participants are considering changing their future career direction, of whom 38% are contemplating leaving the oncology profession altogether and 28% deliberating moving to a role within industry. This is on a background of perceived declining support from employers and national/global bodies.

Although our findings are compelling, this study has its limitations. Survey III had a substantial number of participants but this still only constitutes approximately 5% of the ESMO membership base. Participants were mainly medical oncologists, more established in their careers with the majority based in Europe. Thus, these findings may not necessarily be representative of the needs of the global oncology workforce, particularly those in more resource-constrained health care systems. Findings from the 2003 SARS experience suggests that those with the most direct contact with patients, including nurses, administrative staff, and ancillary workers, had the highest level of stress.16 These occupational groups are not well represented in our survey series. Attrition in the oncology nursing workforce in particular has already impacted significantly on cancer treatment delivery.7 Nurses are also predominantly female and are the largest health care professional group providing frontline care, both of which are risk factors for burnout.2,12

Our study methodology involved optional online surveys which are associated with the risk of participant self-selection bias. On balance, however, this remains the

---

(A) various factors related to job demands. (B) personal and professional resources available to participants.

Proportions (percentage, %) are displayed as colours ranging from blue to red (with red denoting cause for concern i.e. increased job demands for (A) and decreased job resources in (B), as shown in the key. Groups were compared using Chi-square test for trend (Survey I versus Survey II versus Survey III, where available).

*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

ns, not significant; n/a, not applicable.

See also Supplementary Table S3, available at https://doi.org/10.1016/j.esmoop.2021.100374.
optimal methodology for accessing a wider audience within the constraints and work pressures of oncology professionals working on the frontline during the COVID-19 pandemic. Our survey provides indicators of distress in participants but does not provide a definitive understanding of their mental health. As the WBI has been cross-validated with an increased risk of suicide, depression, and anxiety there may be even graver psychological consequences associated with our study findings.\textsuperscript{10,17} Importantly, the impact of additional factors such as prolonged separation from loved ones should also not be underestimated.

Although the findings of the ESMO Resilience Taskforce Survey series are cause for concern, there are also reasons for optimism. Survey III highlights a significant increase in available well-being support services compared with pre-pandemic levels. Our data have allowed us to infer longitudinal trends, but they do not provide us with an indication of future trends particularly given the dramatic changes in the global landscape that have ensued since Survey III was undertaken, with many regions experiencing greater social freedoms. These are likely to be providing psychological relief and improvements in personal circumstances, although the prevailing sense of professional uncertainty with the spectre of rising case numbers remains. There is already some early evidence, though, of resilience in health services, with oncology departments experiencing a return back to normal or higher clinical activity than before the pandemic.

The COVID-19 pandemic has also provided an opportunity for positive transformation. There are a number of adaptations to service delivery that should perhaps continue post-pandemic. For instance, the beneficial impact on equitable access to clinical trials by facilitating greater access to telehealth encounters has been notable, particularly for patients based in non-metropolitan settings who often face greater travel time and financial toxicity to access novel therapies.\textsuperscript{18} Remote site visits, greater use of electronic signatures, and virtual meetings have also improved efficiency in clinical trial delivery which has been beneficial for all stakeholders. For example, in Singapore, the pharmacy drug courier service has allowed a substantial number of patient prescriptions to be sent directly to their homes, improving overall quality of care.\textsuperscript{19} Virtual outpatient patient visits conducted by Clinical Pharmacy Specialists in New York City optimised treatment delivery and patient safety whilst reducing in-person visits.\textsuperscript{20}

Although our survey participants have highlighted ongoing challenges with accessing professional development opportunities, international initiatives such as the introduction of virtual oncology fellowships and dedicated educational webinars have been examples of positive responses.\textsuperscript{21} The increased access to virtual oncology conferences and virtual mentorship programmes have also proven popular.\textsuperscript{22} In the long term, these initiatives may increase the ability of more staff to participate in professional development activities while balancing other commitments and mitigating financial cost.

A focus group study of American oncologists during the pandemic identified that many participants were strongly considering working part-time or taking early retirement.\textsuperscript{23} Although this may seem concerning from a workforce planning viewpoint similar to our study, these career decisions were triggered by COVID-19-related work changes providing opportunity for self-care and reprioritisation of work-life balance. This examination of personal and professional values should be encouraged as essential for healthy careers and workplaces. It also highlights the importance of workplace arrangements that promote flexibility and work-life balance. Despite Melbourne being the city worst affected by the COVID-19 pandemic in Australasia, modifications to practice in response to the pandemic were well received by radiation oncologists, with the vast majority of staff (the majority of whom were female) reporting satisfaction with their work arrangements, particularly those with children.\textsuperscript{24} The ability to work from home has been reported as a positive experience associated with reduced burnout if adequate information technology and childcare support is available.\textsuperscript{25} This suggests that judicious changes to standard workplace practice as a result of COVID-19 restrictions have the potential to improve workplace flexibility and quality.

The ESMO Resilience Taskforce survey series highlights the pivotal importance of ameliorating the distress of cancer professionals with a critical focus on prioritising workforce retention. National and international stakeholders must act together as we recover from the COVID-19 crisis to promote the well-being of oncology professionals. Further detailed analyses, including multivariate analyses on factors influencing outcomes of interest and interrogation of qualitative data collected from the survey series, are underway. The ESMO Resilience Task Force will shortly be releasing a position paper with some key recommendations. Ultimately, a healthy oncology workforce is a matter of urgency. It is essential for supporting the well-being of our patients and their loved ones, many of whom know that their time together is limited.

ACKNOWLEDGEMENTS

We would like to thank all participants for taking part, and national societies and organizations who helped distribute the survey. We would also like to thank Francesca Longo, Mariya Lemosle, and Katharine Fumasoli from the ESMO Head Office for providing vital administrative support for the delivery of this study.

FUNDING

This work was supported by the European Society for Medical Oncology (ESMO): for license to use Qualtrics (online survey platform), and publication of figure fee.

DISCLOSURE

KHL is currently funded by the Wellcome-Imperial 4i Clinical Research Fellowship, and reports speaker honorarium from Janssen, outside the submitted work. KP’s institution...
received speaker fees or honoraria for consultancy/ advisory roles from AstraZeneca, Eli Lilly, Gilead Sciences, Medscape, Merck Sharp & Dohme (MSD), Novartis, Pfizer, Pierre Fabre, Hoffmann La Roche, Mundipharma, PharmaMar, Seagen, Teva, and Vifor Pharma; KP’s institution received research grants from MSD and Sanofi; KP received travel support from AstraZeneca, Novartis, Pfizer, PharmaMar, and Roche; all outside the submitted work. CO reports research funding and honoraria from Roche; travel grant and honoraria from medac Pharma and Ipsen Pharma; and travel grant from PharmaMar; outside the submitted work. EE reports speaker honoraria, travel support and advisory board: Bayer, Roche, Servier, Amgen, Pierre-Fabre, Sanofi Aventis, MSD, and Merck Serono; outside the submitted work. TA reports personal fees from Pierre Fabre and CeCava; personal fees and travel grants from Bristol Myers Squibb (BMS); grants, personal fees, and travel grants from Novartis; and grants from NeraCare, Sanofi, and SkylineDx; all outside the submitted work. PG reports personal fees from Roche, MSD, BMS, Boehringer-Ingelheim, Pfizer, AbbVie, Novartis, Lilly, AstraZeneca, Janssen, Blueprint Medicines, Takeda, Gilead, and ROVI, outside the submitted work. ML acted as a consultant for Roche, AstraZeneca, Lilly, and Novartis, and received honoraria from Theramex, Roche, Novartis, Takeda, Pfizer, Sandoz, and Lilly, outside the submitted work. CBW reports speaker honoraria, travel support, and participation in advisory boards: Bayer, BMS, Celgene, GlaxoSmithKline (GSK), Merck, Rafael, RedHill, Roche, Servier, Shire/Baxalta, Sirtex, and Taiho, as well as research support from Roche, outside the submitted work. JBAHG reports personal fees for advisory role in Neogene Tx; grants and fees paid to institution from BMS, MSD, Novartis, BioNTech, Amgen; and fees paid to institution from Achilles Tx, GSK, Immunocore, Ipsen, Merck Serono, Molecular Partners, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures, Vaximm; outside the submitted work. CH reports being Director of a private company Hardy People Ltd, outside the submitted work. SB reports research grant (institution) from AstraZeneca, Tesaro, and GSK; honoraria for advisory boards or lectures from Amgen, AstraZeneca, Gennab, Immunogen, Mersana, MSD, Merck Serono, OncXerna, Pfizer, Roche, Shattuck Labs, Clovis, Takeda outside the submitted work. KM, KK, MOC, ET, BD, and GM have declared no conflicts of interest.

REFERENCES

1. Mayor S. COVID-19: impact on cancer workforce and delivery of care. *Lancet Oncol*. 2020;21(5):633.
2. Paterson C, Gobel B, Gosselin T, et al. Oncology nursing during a pandemic: critical reflections in the context of COVID-19. *Semin Oncol Nurs*. 2020;36(3):151028.
3. Chazan G, Franchini F, Alexander M, et al. Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. *ESMO Open*. 2020;5(6):e001090.
4. Banerjee S, Lim KHI, Murali K, et al. The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration. *ESMO Open*. 2021;6(2):100058.
5. Lim KHI, Murali K, Kampiosioras K, et al. The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II. *ESMO Open*. 2021;6(4):100199.
6. Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. *Lancet Oncol*. 2020;21(8):1023-1034.
7. Clark JJ, Dwyer D, Pinwill N, Clark P, Johnson P, Hackshaw A. The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis. *Lancet Oncol*. 2021;22(1):66-73.
8. Campbell C, Sommerfield T, Clark GRC, et al. COVID-19 and cancer screening in Scotland: A national and coordinated approach to minimising harm. *Prev Med*. 2021;151:106606.
9. Richards M, Anderson M, Carter P, Ebert BL, Mossialos E. The impact of the COVID-19 pandemic on cancer care. *Nat Cancer*. 2020;1:565-567.
10. Dyrbye LN, Satle D, Sloan J, Shanafelt TD. Utility of a brief screening tool to identify physicians in distress. *J Gen Intern Med*. 2013;28(3):421-427.
11. Dyrbye LN, Satle D, Shanafelt T. Ability of a 9-item Well-Being Index to identify distress and stratify quality of life in US workers. *J Occup Environ Med*. 2016;58(8):810-817.
12. Murali K, Makker V, Lynch J, Banerjee S. From burnout to resilience: an update for oncologists. *Am Soc Clin Oncol Educ Book*. 2018;38:862-872.
13. Murali K, Banerjee S. Let’s address burnout in oncologists and reimage the way we work. *Nat Rev Clin Oncol*. 2019;16(1):1-2.
14. Jiwani S, Ranganathan P, Tiwari V, et al. COVID-19 pandemic and its gendered impact on Indian physicians. *JCO Glob Oncol*. 2021;7:1093-1100.
15. Garrido P, Adjei AA, Bajpai J, et al. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. *ESMO Open*. 2021;6(3):100131.
16. Wu P, Fang Y, Guan Z, et al. The psychological impact of the SARS epidemic on hospital employees in China: exposure, risk perception, and altruistic acceptance of risk. *Can J Psychiatry*. 2009;54(5):302-311.
17. Dyrbye LN, Satle D, Sloan J, Shanafelt TD. Ability of the physician well-being index to identify residents in distress. *J Grad Med Educ*. 2014;6(1):78-84.
18. Pennell NA, Dillmon M, Levit LA, et al. American Society of Clinical Oncology road to recovery report: learning from the COVID-19 experience to improve clinical research and cancer care. *J Clin Oncol*. 2021;39(2):155-169.
19. Kanesvaran R, Chia CS, Yap SP, et al. Cancer versus COVID-19: a coordinated Disease Outbreak Response System (DORS) to combat COVID-19 at the National Cancer Centre Singapore. *Ann Acad Med Singap*. 2020;49(10):807-809.
20. Yerram P, Thackray J, Modelevsky LR, et al. Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City. *J Oncol Pharm Pract*. 2021;27(2):389-394.
21. Gillett C, Mason S, Fleming L, Mayer DK, Bryant AL. An academic to virtual fellowship. *J Clin Nurs*. 2021.
22. Morgan G, Tagliamento M, Lamberti M, et al. Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. *ESMO Open*. 2021;6(2):100104.
23. Hubloky FJ, Symington BE, McFarland DC, et al. Impact of the COVID-19 pandemic on oncologist burnout, emotional well-being, and moral distress: considerations for the cancer organization’s response for readiness, mitigation, and resilience. *JCO Glob Oncol*. 2021;7:1365-374.
24. Rykers K, Tacey M, Bowes J, et al. Victoria (Australia) radiotherapy response to working through the first and second wave of COVID-19: Strategies and staffing. *J Med Imaging Radiat Oncol*. 2021;55(3):374-383.
25. Hoffman KE, Garner D, Koong AC, Woodward WA. Understanding the intersection of working from home and burnout to optimize post-COVID19 work arrangements in radiation oncology. *Int J Radiat Oncol Biol Phys*. 2020;108(2):370-373.